I doubt it does. The market doesn't take kindly to fluff PRs. I'm all for getting updates, but this PR just reeks of "desperation," almost like Dr. Missling felt compelled to throw some steak to the hungry lions demanding food.
Nobody cares about A-273 as a blood pressure medication. Honestly, how many of us would have invested in the company if this was the indication they're treating? At best, it's fluff material to pass the time until the trials start. At worst, it's prelude to a potential pivot if Anavex were to fail its CNS trials; sort of how Viagra or Rogaine were both intended originally as blood pressure medications.
Did the stock deserve to dump 10% on this news? Of course not. But it just goes to show that sometimes less is better. Be careful for what you wish for. MIssling needs to understand that the ONLY PR that matters now is news that one of the P3 trials is going to begin. Until we get that, I see this stock ebbing and flowing but ultimately bleeding out until there's news that the market truly wants to hear.
News 
Market Data 
Discover 
